Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Viprinex set for phase III in the summer

March 17, 2005

Savient terminating phase II Prosaptide study

March 17, 2005

Altea Therapeutics' hydromorphone transdermal patch enters phase II

March 17, 2005

Specific GABAAalpha2/3 agonist shows potential for the treatment of anxiety

March 16, 2005

mGluR5 antagonist exerts antidepressant effects in rodent models

March 16, 2005

Antisense Therapeutics halts phase IIa study of ATL-1102 for MS

March 16, 2005

Avanir acquires additional Neurodex rights

March 16, 2005

Phase III trials planned for BEMA fentanyl

March 16, 2005

CB2 agonist with notable PK profile shows potential for treating inflammatory pain

March 15, 2005

Improved cognitive function in elderly patients treated with Cymbalta for depression

March 15, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...